FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma

medpagetoday.com·Aug 6, 2026 · 5 g fa

FDA Finally OKs Twice-Rejected Melanoma Drug

qz.com·Aug 7, 2026 · 4 g fa

FDA approves Replimune's Tudriqev melanoma drug on third try

endpoints.news·Aug 6, 2026 · 4 g fa

Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections

biopharmadive.com·Aug 6, 2026 · 5 g fa

Replimune rebounds to win FDA approval of melanoma drug

fiercepharma.com·Aug 6, 2026 · 4 g fa

Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle

statnews.com·Aug 6, 2026 · 4 g fa

FDA approves Replimune melanoma drug previously rejected twice

endpoints.news·Aug 3, 2026 · 8 g fa

FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients

benzinga.com·Aug 3, 2026 · 8 g fa

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Novartis (NYSE:NVS)

morningstar.com·Aug 6, 2026 · 5 g fa

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

morningstar.com·Aug 4, 2026 · 7 g fa

Correction to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31